![中国临床肿瘤学会(CSCO)恶性血液病诊疗指南·2020](https://wfqqreader-1252317822.image.myqcloud.com/cover/547/33145547/b_33145547.jpg)
上QQ阅读APP看书,第一时间看更新
2.5 治疗
2.5.1 诱导缓解治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image141.jpg?sign=1738832073-RyLPXcpxwajB01Q1HM5o1NgoyyC6gqgb-0-4a0a0084288809d887457241e092c306)
所有急性髓系白血病患者,可以参加临床研究的情况下,均建议首选参加临床研究。在没有临床研究的情况下,可以参照下述建议进行治疗。本章节为年龄<60岁成人患者。
2.5.2 诱导治疗后检测
诱导治疗过程中,建议在骨髓抑制期(停化疗后第7~14天左右)、恢复期(停化疗后第21~28天左右)复查骨髓。根据骨髓抑制期、血象恢复期的骨髓情况进行治疗调整。
(1)标准剂量Ara-C诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image142.jpg?sign=1738832073-f2J7PfyS8rhUV7MFSOycZfQE3rfZNVEv-0-a891d3d3d9fd00e69a4cf5d06364a8e3)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image143.jpg?sign=1738832073-PlK3qubCnx3CEgJ9pYjA1jldVEJhntVH-0-00157becee4b4efc8fce425da6b39d3f)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image144.jpg?sign=1738832073-qMtup2GSAtd3hIPvFBPZGiVB1WYYNubp-0-2bf2262ea9dda1f21b4f66b40508115e)
(2)含中大剂量Ara-C方案的诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image145.jpg?sign=1738832073-yPZtEbezD4p077jgJMr0VR0etpFr5x7y-0-a4fb10c8fc665c44eb44c5a11c370257)
2.5.3 AML完全缓解后治疗的选择
按遗传学预后危险度分组治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image146.jpg?sign=1738832073-XCA8ttTKSNmwo5eRbmytaWov5H19I2qi-0-909409016b2b7cbfbc74cc5037d45ac9)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image147.jpg?sign=1738832073-9hu8wxjFf610otNV7FZzikO6LRAwBkDJ-0-32670b716ce655f9461c58387938388c)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image148.jpg?sign=1738832073-7sGXYXRLaibYEbb7eyCYqukRqax1iHKk-0-1dd7028340c48b6df80e68ae403e42a2)